The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study ... use as a weight-loss ...

For the study, researchers analyzed the ... There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

"The use of GLP-1 receptor ... before our study, it had not been examined on a truly national scale." Following semaglutide's approval for chronic weight management, a shift in the drug's ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows. Not only is ...

A new study suggests that GLP-1 agonist medications ... people with opioid use and more than 800,000 with alcohol use disorder. Those who took Ozempic or a similar drug had a 40% lower chance ...

Consumers using GLP ... 1 use, decreasing by an average of 6.7% to 11.1%. “Overall, the results show that GLP-1 users reduce spending on high-calorie, high-sugar or high-fat items,” the study ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by ... whether exenatide use was associated with ...